Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nolatrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolatrexed SCHEMBL29420099 | 0.99 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL316632 | 0.99 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL27935384 | 0.99 | TYMS (0.97) | TYMSDHFR | |
| SCHEMBL7826662 | 0.87 | TYMS (1.00) | TYMS | |
| Nolatrexed SCHEMBL18489 | 0.80 | TYMS (0.66) | TYMSDHFR | |
| Nolatrexed SCHEMBL1649851 | 0.79 | TYMS (0.65) | TYMSDHFR | |
| SCHEMBL16807869 | 0.76 | TYMS (0.61) | TYMSDHFR | |
| SCHEMBL7827130 | 0.74 | TYMS (1.00) | TYMSDHFR | |
| SCHEMBL7831197 | 0.72 | TYMS (1.00) | TYMSDHFR | |
| SCHEMBL27555186 | 0.72 | TYMS (0.58) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | claimed |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-02-11 | — | — | US | claimed |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-09-03 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | claimed |
| CN-1857213-A | Slow released anticancer injection with both antimetabolite and cellular poison medicine | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1857211-A | Sustained-release injection containing nolatrexed and synergist thereof | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1857208-A | Anticancer sustained-release injection loaded with antimetabolite and synergist thereof | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1850041-A | Anticancer medicine slow-release preparation containing platinum compound and its synergist | SHUAIHUA MEDICINE SCIENCE TECH (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1850037-A | Compound anti-cancer slow-release injected containing blood vessel inhibitor | LANJIN BIOLOG ENGINEERING CO L (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1846672-A | Anticancer medicine composition containing antimetabolite | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846689-A | Slow-released anticancer prepn containing taxane and its synergist | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846670-A | Anticancer implant | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | BERRY DAVID ALLEN (US) | 2004-01-08 | — | — | US | claimed |
| WO-2000009131-A1 | DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS | WARNER-LAMBERT COMPANY (US) | 2000-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885 |
| US-20040006042-A1 | Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers | ABCB1, ABCC1, DPYD | TYMS 267/4885DHFR 81/4885 |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | TYMS 68/4885DHFR 6/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | TYMS 16/4885DHFR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.